Objetivo
Over the past two decades, the pharmaceutical industry has witnessed an exponential growth in approved covalent drugs. The majority of such drugs incorporate a chemical warhead, a mild electrophilic reactive functional group that forms covalent bonds in a reversible or irreversible manner with nucleophilic aminoacid residues. The aim of this proposal is to assess the viability of a new chemical warhead in the discovery of novel kinase inhibitors.
Palabras clave
Programa(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régimen de financiación
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsInstitución de acogida
FUNDACIO PRIVADA INSTITUT CATALA D'INVESTIGACIO QUIMICA
Aportación neta de la UEn
€ 150 000,00
Dirección
AVENIDA PAISSOS CATALANS 16
43007 Tarragona
España
43007 Tarragona
España
Región
Este
Cataluña
Tarragona
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos